We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
IMIDAZOLIDIN DERIVATIVE A NOVEL ANTI COLORECTAL CANCER AGENT.
- Authors
Alrammahi, Faez A.; Abbas Al-Kelaby, Khalida K.
- Abstract
The research includes the preparation of new heterocyclic imidazolodine-4-one derivative,starting from 2- hydroxy-5-((4-nitrophenyl)diazenyl)benzaldehyde (F1). This work involved the synthesis and identification of imidazolodine-2- one derivative (F2) from the Schiff base derivative(F1). These compounds were characterized by Fourier-transform infrared spectroscopy (FTIR) and the Proton nuclear magnetic resonance (1H-NMR) spectrum. The biological activity of the Imidazolidine derivative was also investigated by the thiazolyl blue tetrazolium bromide (MTT) cytotoxicity test on the LS -174T colorectal adenocarcinoma cells,the African green monkey kidney (VERO) cells and the assessment of the concentration that inhibits the growth of 50% of cell viability (IC50). Doxorubicin (DOX) and 5-Fluorouracil (5-FU) were also used for comparative goals. The results showed that Imidazolidine derivative was effectively and significantly inhibited the cell proliferation (p<0.00001) by decreasing the viability of LS -174T cells at different concentrations, which involved 1, 10, 50, 100, 250, 500 and 1000 μg/ml, with a half maximal inhibitory concentration (IC50) of 54.406μg/ml. The DOX and 5-FU IC50 values were 63.140 μg/ml and 55.006 μg/ml, respectively. We concluded that the Imidazolidine derivative has an anticancer effect against the LS -174T colorectal carcinoma cell line.
- Subjects
IMIDAZOLIDINES; COLON cancer; SCHIFF base derivatives; FOURIER transform infrared spectroscopy; DOXORUBICIN
- Publication
Biochemical & Cellular Archives, 2020, Vol 20, Issue 1, p2051
- ISSN
0972-5075
- Publication type
Article
- DOI
10.35124/bca.2020.20.1.2051